louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00664885: Effectiveness of Cultural Sensitive Collaborative Treatment of Depressed Chinese
Official title: Effectiveness of Cultural Sensitive Collaborative Treatment of Depressed Chinese in Primary Care
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depression
Keywords: non-psychiatric
clinics
Lead sponsor: Mackay Memorial Hospital
Sponsor class: OTHER
Collaborators: name: National Health Research Institutes, Taiwan
First posted: 2008-04-23
Enrollment: 280
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is a randomized controlled trial to test whether Culturally Sensitive Collaborative Treatment (CSCT) would improve the outcome of depressed patients visiting non-psychiatric settings in Taiwan.


Eligibility criteria: Inclusion Criteria:

* Patients who attend non-psychiatric clinics at the above site.
* Patients with Major Depressive Disorder (MDD), defined as a positive screen using the PHQ-9, confirmed with the SCAN interview.
* Men or women aged 18 or older.
* Able to participate in a clinical diagnostic interview in either Mandarin or Fukienese dialects.
* Individuals who are willing to be followed up concerning their depression symptoms.
* Individuals who have completed a written consent form.

Exclusion Criteria:

* Women who are pregnant, breast-feeding, or planning pregnancy within the next year.
* Patients with serious suicidal risk.
* Patients with unstable medical illnesses.
* Clinical or laboratory evidence of hypothyroidism.
* Patients with comorbid severe mental disorders
* Patients with history of treatment by a psychiatrist in the past 4 months.

Primary outcomes:
measure: Depressed patients who receive CSCT have improved treatment outcomes compared to patients who receive usual care.
timeFrame: 2wk,6 wk,10 wk,14 wk,18 wk,22wk,26wk
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Mackay Memorial Hospital
Study officials:
References:
Clinical trial NCT04285385: Aromatherapy With Lavender Essential Oil as a Complementary Treatment for the Control of Dental Anxiety
Official title: Aromatherapy With Lavender Essential Oil as a Complementary Treatment for the Control of Dental Anxiety in Patients Requiring Third Molar Surgery of the "University Autonomus Benito Juarez of Oaxaca" UABJO School of Dentistry
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Dental Anxiety
Keywords: aromatherapy
lavender
anxiety
Lead sponsor: Universidad Autónoma Benito Juárez de Oaxaca
Sponsor class: OTHER
First posted: 2020-02-26
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Dental anxiety is a common problem in dental care, the aim of this protocol is to evaluate the effect of lavender for the control of anxiety during a surgical dental extraction.


Eligibility criteria: Inclusion Criteria:

* Volunteer to take part in the study
* Healthy patients
* Patients signing the informed consent
* Patients who need surgical removal of third molars

Exclusion Criteria:

* Hypertensive patients
* Patients with nasal congestion problems
* Patients allergic to lavender.
* Patients under treatment with anti depressants

Primary outcomes:
measure: Corah
timeFrame: 45 minutes before dental treatment
measure: Cortisol
timeFrame: 5 minutes Before aromatherapy
measure: Cortisol
timeFrame: 30 minutes after aromatherapy
Secondary outcomes:
measure: Heart rate
timeFrame: 5 minutes Before aromatherapy
measure: Heart rate
timeFrame: 30 minutes after aromatherapy
measure: Respiratory rate
timeFrame: 5 minutes Before aromatherapy
measure: Respiratory rate
timeFrame: 30 minutes after aromatherapy
measure: Arterial pressure
timeFrame: 5 minutes Before aromatherapy
measure: Arterial pressure
timeFrame: 30 minutes after aromatherapy
Other outcomes:
Locations:
Study officials:
affiliation: UABJO
name: Liliana Argueta-Figueroa, DMD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02903485: Bypassing Anesthesiologist Assessment Before Cataract Surgery: a Non Inferiority Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Cataract
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2016-09-16
Enrollment: 578
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study aims to demonstrate that presurgical assessement of patients' risk factors and surveillance during surgery, both performed by nurses, are not inferior to anesthetic team's care, concerning the rate of complications in cataract surgery with topical anesthesia.

The nurse performs the triage of patients based on a chart of risk factors assessment. The triage, according to the presence or not of risk factors, leads to patients' care by an anesthetic team (medical anesthesist for pre-surgical assessement and anesthetic nurse for surveillance during surgery) or to patients' pre-surgical assessement and surveillance during surgery both performed only by nurses.

In the control group, all patients are taken care of by an aesthetic team, with medical pre surgical assessement and surveillance during surgery both performed by anesthetic nurses.


Eligibility criteria: Inclusion Criteria:

* age \> 18 years old
* cataract surgery scheduled with topical anesthetics
* outpatient surgery

Exclusion Criteria:

* presurgical nurse assessment leading to the need for the anesthetic staff presence during surgery
* general, peribulbar or other locoregional anesthesia required by patient's condition
* concomitant surgery planified (glaucoma, vitrectomy...)
* patient's refusal to participate in the study
* no health insurance coverage

Primary outcomes:
measure: Incidence of complications
timeFrame: through study completion, up to 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Fondation Ophtalmologique Adophe de Rothschild
Study officials:
affiliation: Fondation Ophtalmologique Adolphe de Rothschild
name: Jean-Michel Devys, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03760185: Pupil Dilation for Treatment of IFIS
Official title: Enhanced Pupil Dilation in Patients Taking Alpha-Blockers for Potential Treatment of Intraoperative Floppy Iris Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Intraoperative Floppy Iris Syndrome
Lead sponsor: Denver Health and Hospital Authority
Sponsor class: OTHER
First posted: 2018-11-30
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: This is a single arm study in which all enrolled subjects will receive eye drops to only one eye. The alternative eye will serve as the control for efficacy.
Primary purpose: TREATMENT

Brief summary: A novel intervention for targeting the treatment of Intraoperative Floppy Iris Syndrome.

Detailed description: This study explores the effects that medication can have on increasing pupil dilation. Pupil dilation size is important for operative eye procedures. Decreased pupil size is related to increased complication risks in eye surgery. By exploring novel pupil dilation techniques, there is a potential to counteract the effects of poor pupil dilation that is caused by medications such as alpha-blockers. Intraoperative floppy iris syndrome is a syndrome characterized by a floppy iris (IFIS) and poor pupil dilation during surgery that is caused by BPH medications. This study evaluates treatment methods targeting IFIS.

Eligibility criteria: Inclusion Criteria:

1. Adults (18 years old or greater) 3. History of having taken, or currently taking any systemic alpha blocker 2. Ability to consent themselves 3. Ability to apply eye drops themselves TID for 7 days

Exclusion Criteria:

1. Subjects with untreated hypertension or baseline BP \>160
2. Subjects with Thyrotoxicosis
3. Pregnant women or women trying to conceive
4. Prisoners
5. Inability consent
6. Subjects with anatomical narrow angles or who have never had a dilated eye exam
7. Subjects currently prescribed brimonidine tartrate for glaucoma
8. Subjects who take topical or systemic alpha agonists
9. Patients who take monoamine oxidase (MAO) inhibitors
10. Patients with known severe cardiovascular disease

Primary outcomes:
measure: Pupil Dilation Sized of the Treated Eye Compared to the Non-treated Eye
timeFrame: 45 minutes post dilation after 7 days of treatment
Secondary outcomes:
measure: Change in Pupil Diameter of Each Eye After Dilation at the Start of the Study Compared to Pupil Post Dilating Drops at the End of the Study
timeFrame: 45 minutes post dilation after 7 days of treatment
Other outcomes:
Locations:
city: Denver
country: United States
facility: Denver Health
state: Colorado
Study officials:
affiliation: Denver Health
name: Cristos Ifantides, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06057285: Efficacy of an Augmented Reality Application Developed for ACLs Training on the Knowledge and Skill Levels of Nurses
Official title: Efficacy of an Augmented Reality Application Developed for ACLs Training on the Knowledge and Skill Levels of Nurses
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: ACLs Learning
Lead sponsor: National Cheng-Kung University Hospital
Sponsor class: OTHER
First posted: 2023-09-28
Enrollment: 102
Sex: ALL
Minimum age (years): 22
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Background: Having Advanced Cardiac Life Support (ACLs) skills is essential for nurses. During the COVID-19 pandemic, augmented reality (AR) technologies were incorporated into medical education to increase learning motivation and accessibility.

Objectives: To determine whether using augmented reality for educational applications can significantly improve first aid cart learning, learning motivation, cognitive load, and system usability among nurses in ACLs training of nurses.

Design: The present study was a quasi-experiment study. Settings: The research setting was a medical center in southern Taiwan Participants: In total, 102 nurses completed the course, with 43 nurses in the AR group and 59 nurses in the control group.

Methods: An ACLs cart training course was developed using augmented reality (AR) technologies in the first stage. However, the efficacy of the developed ACLs training course was evaluated.

Detailed description: Application Augmented Reality for ACLs training of Registered Nurse

Eligibility criteria: Inclusion Criteria: Nurses who were aged 20 years or older, could speak and read Mandarin, and completed the questionnaire after the research objective was explained were recruited.

Exclusion Criteria: Nurses without mobile devices were excluded.

Primary outcomes:
measure: ACLs learning outcomes
timeFrame: one hour
Secondary outcomes:
Other outcomes:
Locations:
city: Tainan
country: Taiwan
facility: Wan-Na Sun
state: no-US
Study officials:
References:
Clinical trial NCT01843985: Observational Study of Survival Outcomes of Stage IV Cancer Patients
Official title: Observational Study of Survival Times of Stage IV Cancer Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Stage IV Cancer (Solid Tumors Only)
Survival
Keywords: Stage IV cancer
Survival
Lead sponsor: Cure Cancer Worldwide Corporation
Sponsor class: INDUSTRY
First posted: 2013-05-01
Enrollment: 120
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Sampling method: NON_PROBABILITY_SAMPLE
Study population: primary care clinic

Brief summary: Patients diagnosed with Stage IV cancer (solid tumors only) are evaluated to determine whether they are candidates for traditional chemotherapy. If eligible, patients are offered traditional chemotherapy, low-dose chemotherapy, or palliative care. If ineligible, patients are offered low-dose chemotherapy or palliative care. Patients will be monitored for 5 years and survival data recorded.


Eligibility criteria: Inclusion Criteria:

* Presenting with Stage IV cancer (solid tumors only)

Exclusion Criteria:

* Patient declines inclusion

Primary outcomes:
measure: survival
timeFrame: months 1, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 60
Secondary outcomes:
Other outcomes:
Locations:
city: Yang Ling
country: China
facility: Yang Ling Demonstration Zone Hospital
state: Shaanxi
Study officials:
References:
Clinical trial NCT03949985: Longitudinal Hemostatic Profile After Stopping Estroprogestative Contraceptives
Official title: Longitudinal Hemostatic Profile After Stopping Estroprogestative Contraceptives: a Prospective Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Venous Thromboembolism
Contraception
Lead sponsor: University Hospital, Geneva
Sponsor class: OTHER
First posted: 2019-05-14
Enrollment: 103
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women aged 18-50 years who are current users of estrogenic contraceptives and have decided to stop it or replace it with a non-estrogenic contraceptive.

Women aged 18-50 years who are not current users of estrogenic contraceptives.

Brief summary: This prospective cohort evaluates the longitudinal profile of hemostatic biomarkers during the first 3 months after having stopped a combined oral contraceptive.

Detailed description: Women using a combined oral contraceptive (COC) and who have decided to stop it or switch it to a non-estrogenic contraceptive are included. At baseline, before the COC is stopped, and at multiple time points during the 3 months of follow-up, blood will be drawn to evaluate the hemostatic profile. Findings are compared with a control group of women without an estrogenic contraceptive, who are also followed for 3 months.

Eligibility criteria: Inclusion Criteria:

* women
* 18-50 years
* current use (for at least 3 months) of an estrogenic contraceptive with the decision to stop it or replace it with a non-estrogenic contraceptive (estrogen group)
* no current use of an estrogenic contraceptive (control group)

Exclusion Criteria:

* personal history of VTE
* known thrombophilia
* recent medical event (hospitalization, surgery, cancer)
* pregnancy, post-partum period, current breastfeeding

Primary outcomes:
measure: Change in normalized APC sensitivity ratio
timeFrame: Three months
Secondary outcomes:
measure: Change in Endogenous Thrombin Potential (Thrombin Generation Assay)
timeFrame: Three months
measure: Change in concentrations of sex hormone-binding globulin
timeFrame: Three months
measure: Change in fibrinolysis assay
timeFrame: Three months
measure: Change in individual coagulation factors
timeFrame: Three months
measure: Contraception-related satisfaction
timeFrame: Three months
Other outcomes:
Locations:
city: Geneva
country: Switzerland
facility: Geneva University Hospitals
Study officials:
References:
Clinical trial NCT02075385: Swallowing Intervention During Radiochemotherapy on Head and Neck Cancer
Official title: Randomized Phase II Trial: Swallowing Speech Pathology Intervention During Radiochemotherapy on Patients With Head and Neck Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Head Neck Cancer
Swallowing Disorders
Keywords: Dysphagia
speech language therapy
quality of life
induction chemotherapy
concurrent chemoradiotherapy
Lead sponsor: Barretos Cancer Hospital
Sponsor class: OTHER
First posted: 2014-03-03
Enrollment: 94
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: General Objective: To evaluate the swallowing results of speech pathologist rehabilitation of advanced oropharynges, larynx and hypopharynx cancer patients during neoadjuvant chemotherapy and radiotherapy concomitant to chemotherapy.

Methods and Casuistic: Randomized clinical trial phase II. 80 patients with advanced oropharynges, larynx and hypopharynx cancer diagnoses from Barretos Cancer Hospital, which had the proposal of neoadjuvant chemotherapy followed by radiotherapy combined with chemotherapy. Patients are randomized on two groups: control group and speech pathology therapy group

Detailed description: To evaluate and compare the swallowing and life quality swallowing on a group undergoing to speech pathology therapy (intervention) and a control group (no intervention).

Eligibility criteria: Inclusion Criteria:

* Head and neck squamous cell carcinoma
* Indication for the protocol treatment of neoadjuvant chemotherapy followed by radiotherapy concomitant to chemotherapy.
* Oropharynges, larynx and hypopharynx advanced cancer (T3 or T4), classified as resectable;
* 18 years old or older;
* informed consent signed before any specific procedure

Exclusion Criteria:

* Previous head and neck surgery
* Previous radiotherapy or chemotherapy
* Previous history of neoplasia, excepted for in situ carcinoma of endometrial (uterine) cancer, skin basal cell or squamous cell carcinoma;
* Severe laryngeal aspiration during all consistencies swallowing evaluated thought videofluoroscopy
* Patients with cognitive deficit which could not comprehend the speech pathology intervention.

Primary outcomes:
measure: Swallowing function
timeFrame: up to 6 months after concurrent phase.
Secondary outcomes:
Other outcomes:
Locations:
city: Barretos
country: Brazil
facility: Barretos Cancer Hospital
state: São Paulo
Study officials:
affiliation: Fundação Pio XII - Hospital de Câncer de Barretos
name: André L Carvalho, PHD
role: STUDY_CHAIR
affiliation: Fundação Pio XII - Hospital de Câncer de Barretos
name: Luciano S Viana, PHD
role: STUDY_DIRECTOR
affiliation: Fundação Pio XII - Hospital de Câncer de Barretos
name: Alexandre Jacinto, MD
role: STUDY_DIRECTOR
affiliation: Fundação Pio XII - Hospital de Câncer de Barretos
name: Juliana Portas, MSC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03518385: Intracavitary Fluid and Position of C-section-scar
Official title: Does the Presence of Intracavitary Fluid During Hormonal Stimulation for IVF Depends on the Position of C-section-scar?
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Fluid Uterus
Lead sponsor: ART Fertility Clinics LLC
Sponsor class: OTHER
First posted: 2018-05-08
Enrollment: 104
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing IVF treatment in the IVI Middle East Clinic Abu Dhabi and Dubai, due to secondary infertility and delivery with at least one previous C-section.

Brief summary: Does the presence of intracavitary fluid during hormonal stimulation for IVF depends on the position of C-section-scar ?

Detailed description: To evaluate the correlation between the presence of intracavitary fluid and the position of the C-section-scar in relation to the uterine fundus and the inner cervical os.

To this end, we will compare measured variables, in patients with intracavitary fluid and without intracavitary fluid.

Eligibility criteria: Inclusion Criteria:

* Patients above an age of 18 years.
* Patients performing IVF treatment.
* One or multiple C-sections.
* C-scar region visible during trans-vaginal scan.

Exclusion Criteria:

* Patients who were IUD carriers in the last 3 months.

Primary outcomes:
measure: Presence/Absence of ICF
timeFrame: 1 year and 6 months
Secondary outcomes:
measure: Thickness of fluid accumulation in the cavity
timeFrame: 1 year and 6 months
Other outcomes:
Locations:
city: Abu Dhabi
country: United Arab Emirates
facility: IVI Middle East Fertility Clinic
Study officials:
affiliation: ART Fertility Clinics LLC
name: Human Fatemi, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bij de Vaate AJ, Brolmann HA, van der Voet LF, van der Slikke JW, Veersema S, Huirne JA. Ultrasound evaluation of the Cesarean scar: relation between a niche and postmenstrual spotting. Ultrasound Obstet Gynecol. 2011 Jan;37(1):93-9. doi: 10.1002/uog.8864.
citation: Tower AM, Frishman GN. Cesarean scar defects: an underrecognized cause of abnormal uterine bleeding and other gynecologic complications. J Minim Invasive Gynecol. 2013 Sep-Oct;20(5):562-72. doi: 10.1016/j.jmig.2013.03.008. Epub 2013 May 14.
citation: Vervoort AJ, Uittenbogaard LB, Hehenkamp WJ, Brolmann HA, Mol BW, Huirne JA. Why do niches develop in Caesarean uterine scars? Hypotheses on the aetiology of niche development. Hum Reprod. 2015 Dec;30(12):2695-702. doi: 10.1093/humrep/dev240. Epub 2015 Sep 25.
citation: Chien LW, Au HK, Xiao J, Tzeng CR. Fluid accumulation within the uterine cavity reduces pregnancy rates in women undergoing IVF. Hum Reprod. 2002 Feb;17(2):351-6. doi: 10.1093/humrep/17.2.351.
citation: Lawrenz B, Melado L, Garrido N, Coughlan C, Markova D, Fatemi H. Isthmocele and ovarian stimulation for IVF: considerations for a reproductive medicine specialist. Hum Reprod. 2020 Jan 1;35(1):89-99. doi: 10.1093/humrep/dez241.